<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365922</url>
  </required_header>
  <id_info>
    <org_study_id>ARTFL8101</org_study_id>
    <secondary_id>1U54NS092089-01</secondary_id>
    <nct_id>NCT02365922</nct_id>
  </id_info>
  <brief_title>Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)</brief_title>
  <acronym>ARTFL</acronym>
  <official_title>Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 &amp; 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Bluefield Project to Cure Frontotemporal Dementia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tau Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of&#xD;
      rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes:&#xD;
      frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration&#xD;
      syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is&#xD;
      to build a FTLD clinical research consortium to support the development of FTLD therapies for&#xD;
      new clinical trials. The consortium, referred to as Advancing Research and Treatment for&#xD;
      Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner&#xD;
      with six patient advocacy groups to manage the consortium. Participants will be evaluated at&#xD;
      14 clinical sites throughout North America and a genetics core will genotype all individuals&#xD;
      for FTLD associated genes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of&#xD;
      rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes:&#xD;
      frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration&#xD;
      syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is&#xD;
      to build a FTLD clinical research consortium (FTLD CRC) to support the development of FTLD&#xD;
      therapies for new clinical trials. The FTLD CRC will be headquartered at UCSF and will&#xD;
      partner with six patient advocacy groups to manage the consortium. Patients will be evaluated&#xD;
      at 13 clinical sites throughout North America and a genetics core will genotype all&#xD;
      individuals for FTLD associated genes.&#xD;
&#xD;
      The study will be divided into 2 projects. The first project will be Preparing for Sporadic&#xD;
      FTLD Clinical Trials and the second project will be a Longitudinal Assessment of Familial&#xD;
      FTLD. Self-registration for an online registry will be available for patients and families&#xD;
      with any FTLD syndrome. Eligible participants for research Projects 1 and 2 FTLD will be&#xD;
      invited to a CRC site for clinical evaluations. All enrolled participants in both research&#xD;
      projects will have a site visit consisting of a neurological exam, medical and family&#xD;
      history, cognitive testing, and a blood draw.&#xD;
&#xD;
      Participants in Project 1 who have a diagnosis of Progressive Supranuclear Palsy Syndrome&#xD;
      will have two additional assessments. A lumbar puncture (LP) will be performed for CSF&#xD;
      collection, and an MRI scan of the brain will be done.&#xD;
&#xD;
      Participants in Project 2: Longitudinal Assessment of familial FTLD will return for a&#xD;
      follow-up visit in 12 months; procedures at the follow-up visit will be identical to those at&#xD;
      baseline. Additionally, asymptomatic participants will undergo MRI scans at both visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">September 2020</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Scores of UDS FTLD Module Tests</measure>
    <time_frame>Baseline, 12 mo.</time_frame>
    <description>Neuropsychological test scores from the Uniform Data Set FTLD Module will be collected and compared across patient populations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progressive Supranuclear Palsy Rating Scale (PSPRS)</measure>
    <time_frame>Baseline</time_frame>
    <description>Scores will be compared among patient populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>Baseline; 12 months</time_frame>
    <description>In asymptomatic family members of FTLD patients, changes from baseline neuroimaging will be assessed 12 months later.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1489</enrollment>
  <condition>FTLD</condition>
  <condition>Progressive Supranuclear Palsy (PSP)</condition>
  <condition>Frontotemporal Dementia (FTD)</condition>
  <condition>Corticobasal Degeneration (CBD)</condition>
  <condition>PPA Syndrome</condition>
  <condition>Behavioral Variant Frontotemporal Dementia (bvFTD)</condition>
  <condition>Semantic Variant Primary Progressive Aphasia (svPPA)</condition>
  <condition>Nonfluent Variant Primary Progressive Aphasia (nfvPPA)</condition>
  <condition>FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)</condition>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <condition>Oligosymptomatic PSP (oPSP)</condition>
  <condition>Corticobasal Syndrome (CBS)</condition>
  <arm_group>
    <arm_group_label>Patients with FTLD or family members</arm_group_label>
    <description>Participants with FTLD syndrome diagnoses and/or strong family histories of FTLD.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum, cell lines and cerebrospinal fluid will be retained by study investigators and&#xD;
      stored at NIH-funded repositories.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of a frontotemporal lobar degeneration (FTLD) syndrome, including&#xD;
        progressive supranuclear palsy (PSP), semantic variant primary progressive aphasia (svPPA),&#xD;
        and frontotemporal dementia with amyotrophic lateral sclerosis (FTD-ALS). Family members of&#xD;
        patients with FTLD syndromes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Inclusion Criteria:Must meet one of the following research diagnostic criteria for a&#xD;
             Frontotemporal lobar degeneration (FTLD) syndrome: behavioral variant frontotemporal&#xD;
             dementia (bvFTD), primary progressive aphasia (PPA), semantic variant primary&#xD;
             progressive aphasia (svPPA), nonfluent variant primary progressive aphasia (nfvPPA),&#xD;
             frontotemporal dementia with amyotrophic lateral sclerosis (FTD/ALS), amyotrophic&#xD;
             lateral sclerosis alone, corticobasal syndrome (CBS), progressive supranuclear palsy&#xD;
             (PSP) or oligosymptomatic PSP (oPSP), or have a strong family history of FTLD&#xD;
             syndromes.&#xD;
&#xD;
          2. Between 18 and 85 (inclusive) years of age.&#xD;
&#xD;
          3. Able to walk (with assistance) at the time of enrollment.&#xD;
&#xD;
          4. Have a reliable study partner who can provide an independent evaluation of&#xD;
             functioning.&#xD;
&#xD;
          5. Speak English or Spanish&#xD;
&#xD;
          6. Have Mini Mental State Exam (MMSE) scores between 15 - 30 (inclusive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known presence of a structural brain lesion (e.g. tumor,cortical infarct) that could&#xD;
             reasonably explain symptoms in a symptomatic participant without a known f-FTLD&#xD;
             causing mutation.&#xD;
&#xD;
          2. Known presence of an Alzheimer's disease causing mutation in PSEN1, PSEN2 or APP; or&#xD;
             neuropathological evidence for Alzheimer's disease as a cause of syndrome (from brain&#xD;
             biopsy).&#xD;
&#xD;
          3. A previous history of Korsakoff encephalopathy, severe alcohol dependence (within 5&#xD;
             years of onset of dementia), frequent alcohol or other substance intoxication, or&#xD;
             other neurological disorder (such as multiple sclerosis)&#xD;
&#xD;
          4. Evidence through history or laboratory testing of B12 deficiency (B12 &lt; 95% of local&#xD;
             laboratory's normal value), hypothyroidism (TSH &gt;150% of normal), HIV positive,renal&#xD;
             failure (creatinine &gt; 2), liver failure (ALT or AST &gt; two times normal), respiratory&#xD;
             failure (requiring oxygen), extra-axial brain tumor (with visible compression of the&#xD;
             brain parenchyma), large cerebral infarct that could account for clinical syndrome,&#xD;
             large confluent white matter lesions (grades 3 or 4, [107] significant systemic&#xD;
             medical illnesses such as deteriorating cardiovascular disease;&#xD;
&#xD;
          5. Current medication likely to affect CNS functions in the opinion of the site PI: long&#xD;
             acting benzodiazepines such as diazepam (short-acting benzodiazepines are OK),&#xD;
             non-SSRI antidepressants (SSRIs or trazodone are OK), no lithium, typical neuroleptics&#xD;
             as listed in the Manual of Procedures, narcotics (codeine is OK, but hold 24 hours&#xD;
             before neuropsychological testing), anticonvulsants (outside of therapeutic ranges),&#xD;
             antihistamines (if taking greater than three times per week; hold 24 hours before&#xD;
             neuropsychological testing).&#xD;
&#xD;
          6. In the site investigator's opinion, the participant cannot complete sufficient key&#xD;
             study procedures, or equivalent assessment of impairment level.&#xD;
&#xD;
          7. For groups where MRI scans are planned procedures, any contraindication for MRI&#xD;
             scanning, such as pacemaker or other implanted metals.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam L Boxer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study PI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard University Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, Mendez M, Kerwin D, Lerner A, Wu CK, Koestler M, Shapira J, Sullivan K, Klepac K, Lipowski K, Ullah J, Fields S, Kramer JH, Merrilees J, Neuhaus J, Mesulam MM, Miller BL. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013 Feb;12(2):149-56. doi: 10.1016/S1474-4422(12)70320-4. Epub 2013 Jan 2.</citation>
    <PMID>23290598</PMID>
  </reference>
  <reference>
    <citation>Boxer AL, Garbutt S, Seeley WW, Jafari A, Heuer HW, Mirsky J, Hellmuth J, Trojanowski JQ, Huang E, DeArmond S, Neuhaus J, Miller BL. Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease. Arch Neurol. 2012 Apr;69(4):509-17. doi: 10.1001/archneurol.2011.1021.</citation>
    <PMID>22491196</PMID>
  </reference>
  <reference>
    <citation>Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH; AL-108-231 Investigators. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul;13(7):676-85. doi: 10.1016/S1474-4422(14)70088-2. Epub 2014 May 27.</citation>
    <PMID>24873720</PMID>
  </reference>
  <reference>
    <citation>Rosen HJ, Alcantar O, Zakrzewski J, Shimamura AP, Neuhaus J, Miller BL. Metacognition in the behavioral variant of frontotemporal dementia and Alzheimer's disease. Neuropsychology. 2014 May;28(3):436-47. doi: 10.1037/neu0000012. Epub 2014 Feb 17.</citation>
    <PMID>24548124</PMID>
  </reference>
  <reference>
    <citation>Rosen HJ, Alcantar O, Rothlind J, Sturm V, Kramer JH, Weiner M, Miller BL. Neuroanatomical correlates of cognitive self-appraisal in neurodegenerative disease. Neuroimage. 2010 Feb 15;49(4):3358-64. doi: 10.1016/j.neuroimage.2009.11.041. Epub 2009 Dec 1.</citation>
    <PMID>19961939</PMID>
  </reference>
  <reference>
    <citation>Rohrer JD, Rosen HJ. Neuroimaging in frontotemporal dementia. Int Rev Psychiatry. 2013 Apr;25(2):221-9. doi: 10.3109/09540261.2013.778822. Review.</citation>
    <PMID>23611351</PMID>
  </reference>
  <reference>
    <citation>Boeve BF. Progressive supranuclear palsy. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S192-4. doi: 10.1016/S1353-8020(11)70060-8. Review.</citation>
    <PMID>22166432</PMID>
  </reference>
  <reference>
    <citation>Boeve BF. The multiple phenotypes of corticobasal syndrome and corticobasal degeneration: implications for further study. J Mol Neurosci. 2011 Nov;45(3):350-3. doi: 10.1007/s12031-011-9624-1. Epub 2011 Aug 19. Review.</citation>
    <PMID>21853287</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>February 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FTLD, PSP, CBD, PPA, FTD, FTD-ALS, CBS, ALS, svPPA, nfvPPA, oPSP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Aphasia</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Frontotemporal Lobar Degeneration</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

